Journal of Shandong University (Health Sciences) ›› 2018, Vol. 56 ›› Issue (1): 17-21.doi: 10.6040/j.issn.1671-7554.0.2017.897

Previous Articles    

Treatment of early breast cancer: more or less? Study from the 2017 American Society of Clinical Oncology Annual Meeting

WANG Shu, PENG Yuan   

  1. Breast Center, Peking University Peoples Hospital, Beijing 100044, China
  • Published:2022-09-27

PDF (PC)

21

Abstract: The treatment of breast cancer is moving forward to precision medicine. American Society of Clinical Oncology Meeting went deep into a full discussion on the addition and subtraction of breast cancer treatment in 2017. The results of many clinical trials were updated in the treatment of early breast cancer, from the traditional surgery, chemo- 山 东 大 学 学 报 (医 学 版)56卷1期 -王殊,等.从2017年美国临床肿瘤学会大会报告看早期乳腺癌治疗加减法 \=-therapy and endocrine therapy, to anti-HER2 therapy and the finding of new therapeutic targets. The meeting gave us a new sight on finding the effective, less injured and economic treatment for the patients with early breast cancer.

Key words: Early breast cancer, American Society of Clinical Oncology, Treatment progress, Chemotherapy, Endocrine therapy, Targeted therapy

CLC Number: 

  • R711
[1] Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer[J]. N Engl J Med, 2002, 347(16): 1233-1241.
[2] Krag DN, Anderson SJ, Julian TB, et al. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial[J]. Lancet Oncol, 2010,11(10): 927-933.
[3] 刘淼,王殊,彭媛,等. ACOSOG Z0011试验标准用于中国前哨淋巴结阳性乳腺癌患者以避免腋窝淋巴结清扫的可行性研究[J]. 中国癌症杂志,2015,25(2): 135-140. LIU Miao, WANG Shu, PENG Yuan, et al. The exportability of the criteria defined by Z0011 trial for selecting patients who are eligible for omitting ALND after a positive SLNB result in China[J]. China Oncology, 2015, 25(2): 135-140.
[4] National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. breast cancer, version 3.2017[EB/OL].[2017-11-10]. http//www.nccn.org/professionals/physician.gls/pdf/breast.pdf.
[5] Morrow M, Abrahamse P, Hofer TP, et al. Trends in reoperation after initial lumpectomy for breast cancer addressing overtreatment in surgical management[J]. JAMA Oncol, Published online, June 5, 2017. doi:10.1001/jamaoncol.2017.0774.
[6] Gluz O, Nitz UA, Christgen M, et al. West German study group phase III PlanB trial: first prospective outcome data for the 21-gene recurrence score assay and concordance of prognostic markers by central and local pathology assessment[J]. J Clin Oncol, 2016, 34(20): 2341-2349.
[7] Harbeck N, Gluz O, Clemens M, et al. Prospective WSG phase III Plan B trial: final analysis on adjuvant 4EC→4Doc vs. 6Docetaxel/Cyclophosphamidein high clinical and intermediate/high genomic risk HER2-negative early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.504.
[8] Blum JL, Flynn PJ, Yothers G, et al. Anthracyclines in early breast cancer: the ABC trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49(NRG Oncology)[J]. J Clin Oncol, 2017, 35(23): 2647-2655.
[9] van Ramshorst MS, van Werkhoven E, Honkoop AH, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: the TRAIN-2 study[J]. Breast, 2016, 29: 153-159. doi: 10.1016/j.breast.2016.07.017.
[10] Davies C, Pan H, Godwin J, et al. Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial[J]. Lancet, 2013, 381(9869): 805-816.
[11] Goss PE, Ingle JN, Pritchard KI, et al. Extending aromatase-inhibitor adjuvant therapy to 10 years[J]. N Engl J Med, 2016, 375(3): 209-219.
[12] Colleoni M, Luo W, Karlsson P, et al. A phase 3 randomized clinical trial of continuous vs intermittent letrozole in postmenopausal women who have received 4-6 years of adjuvant endocrine therapy for lymph node-positive, early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.503.
[13] Sabnis GJ, Macedo LF, Goloubeva O, et al. Stopping treatment can reverse acquired resistance to letrozole[J]. Cancer Res, 2008, 68(12): 4518-4524.
[14] Gianni L, Pienkowski T, Im YH, et al. 5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer(NeoSphere): a multicentre, open-label, phase 2 randomised trial[J]. Lancet Oncol, 2016, 17(6): 791-800.
[15] de Azambuja E, Holmes AP, Piccart-Gebhart M, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer(NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response[J]. Lancet Oncol, 2014, 15(10): 1137-1146.
[16] von Minckwitz G, Procter M, de Azambuja E, et al. A randomized comparison of chemotherapy plus trastuzumab plus placebo versus chemotherapy plus trastuzumab plus pertuzumab as adjuvant therapy in patients with HER2-positive early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.18_suppl.LBA500.
[17] von Minckwitz G, Procter M, de Azambuja E, et al. Adjuvant Pertuzumab and Trastuzumab in early HER2-positive breast cancer[J]. N Engl J Med, 2017, 377(2): 122-131.
[18] Moreno-Aspitia A, Holmes E, Jackisch C, et al. Updated results from the phase III ALTTO trial(BIG 2-06; NCCTG/Alliance N063D)comparing one year of anti-HER2 therapy with lapatinib alone(L), trastuzumab alone(T), their sequence(T→L)or their combination(L+T)in the adjuvant treatment of HER2-positive early breast cancer[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.502.
[19] Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant(HERA)trial[J]. Lancet, 2017, 389(10075): 1195-1205.
[20] Pivot X, Romieu G, Debled M, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer(PHARE): a randomized phase 3 trial[J]. Lancet Oncol, 2013, 14(8): 741-748.
[21] Joensuu H, Bono P, Kataja V, et al. Fluorouracil, epirubicin, and cyclophosphamide with either docetaxel or vinorelbine, with or without trastuzumab, as adjuvant treatments of breast cancer: final results of the FinHer Trial[J]. J Clin Oncol, 2009, 27(34): 5685-5692.
[22] Conte PF, Bisagni G, Frassoldati A, et al. 9 weeks vs 1 year adjuvant trastuzumab in combination with chemotherapy: results of the phase III multicentric Italian Short-HER study[EB/OL].(2017-08-20).[2017-09-19].http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.501.
[23] Bartsch R, de Azambuja E. I-SPY 2: optimising cancer drug development in the 21st century[J]. ESMO Open, 2016, 1(5): e000113. doi:10.1136/esmoopen-2016-000113.
[24] Severson TM, Wolf DM, Yau C, et al. The BRCA1ness signature is associated significantly with response to PARP inhibitor treatment versus control in the I-SPY 2 randomized neoadjuvant setting[J]. Breast Cancer Res, 2017, 19(1): 99. doi: 10.1186/s13058-017-0861-2.
[25] Echavarria I, López-Tarruella S, Márquez-Rodas I. Neratinib for the treatment of HER2-positive early stage breast cancer[J]. Expert Rev Anticancer Ther, 2017, 17(8): 669-679.
[26] Nanda R, Liu MC, Yee D, et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer: result from the I-SPY 2 trial[EB/OL].(2017-08-20).[2017-09-19]. http://ascopubs.org/doi/abs/10.1200/JCO.2017.35.15_suppl.508.
[1] RUAN Xiangyan, CHENG Jiaojiao, DU Juan, GU Muqing. Ovarian tissue cryopreservation and preservation [J]. Journal of Shandong University (Health Sciences), 2022, 60(9): 24-30.
[2] QIN Jing, YANG Fei, CHEN Qian, XIA Handai, LIU Yanguo, WANG Xiuwen. A network meta-analysis of first-line treatment options for patients with advanced driver-gene wild-type and PD-L1 negative non-squamous non-small cell lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 74-82.
[3] WANG Fuli, SUN Yinping, QIN Jie, RONG Jiansheng. Efficacy of DC-CIK cells combined with EGFR-TKI for 35 elderly patients with advanced EGFR-mutant lung cancer [J]. Journal of Shandong University (Health Sciences), 2022, 60(7): 110-117.
[4] Zhuxiu CHU,Wenjing ZHAO,Xiaoyan LI,Xiaoli KONG,Tingting MA,Liyu JIANG,Qifeng YANG. Significance of neoadjuvant chemotherapy and molecular marker changes in 218 women with breast cancer [J]. Journal of Shandong University (Health Sciences), 2021, 59(9): 130-139.
[5] Chuanzhu YAN,Wei WANG,Kunqian JI,Yuying ZHAO. Mitochondrial dysfunction and related brain diseases [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 34-41.
[6] Anjing CHEN,Xun ZHANG. The new strategies of targeting SUMOylation in the treatment of glioma [J]. Journal of Shandong University (Health Sciences), 2020, 1(8): 88-94.
[7] ZHANG Xiqin, ZHU Shouhui, LIU Ning, WANG Yu, CHEN Jiazhen, HU Xudong. Clinical observation of PEG-rhG-CSF in preventing neutropenia in 80 patients with small cell lung cancer treated with concurrent chemoradiotherapy [J]. Journal of Shandong University (Health Sciences), 2020, 58(12): 43-46.
[8] CHEN Bo, ZHANG Lei. Current perspectives of neoadjuvant therapy for breast cancer in 2017 [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 12-16.
[9] LIU Yinhua, ZHAO Jingyi, XIN Ling. Focused updates of American Society of Clinical Oncology Guideline on the use of multigene tests in clinical practice for breast cancer [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 1-5.
[10] SHI Aiping, XU Gege, XIE Xinpeng. Review of neoadjuvant therapy for breast cancer at the St.Gallen conference [J]. Journal of Shandong University (Health Sciences), 2018, 56(1): 6-11.
[11] DONG Wei, XING Naidong, LÜ Jiaju, LIU Shuai, SUN Liang, CAO Qingwei, DONG Yuhao, LIU Zhao, DING Sentai. The therapeutic efficacy of a potent KSP inhibitor S(MeO)TLC against docetaxel-resistant prostate cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 23-30.
[12] ZHAO Zuohui, LI Cuiling, WANG Daoguang, WANG Fengqin, QU Hongyi, DING Sentai, GONG Jing, LÜ Jiaju, YANG Jinghua. Effect of MnSOD acetylation on the proliferation and apoptosis of clear cell renal cell carcinoma cell line 786-O [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(9): 31-35.
[13] DONG Xiuhong. Effect of cognitive-behavioral therapy plus hypnosis in controlling cancer-related fatigue in gastric cancer patients receiving chemotherapy [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(7): 56-59.
[14] XU Zhihong, LIU Rongfeng, WANG Xiaoxiang, FENG Li, YAO Tiezhu, LIU Hong. Efficacy and safety of Yangzheng Xiaoji capsule combined with chemotherapy in treating metastatic breast cancer [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(5): 79-83.
[15] LIU Yongliang, WANG Xiuwen. Postoperative adjuvant chemotherapy related pathological characteristics of elderly rectal cancer and multivariate analysis of prognosis [J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2016, 54(1): 48-51.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright 2018 © Editorial office of Journal of Shandong University (Health Sciences)
Supported by Beijing Magtech Co.Ltd